<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One-hundred-forty patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) due to non-rheumatic, non-<z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> (NVHD) who suffered a cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> were identified </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-three (38%) died of the initial <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The surviving patients were followed up to 9 years without <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In the 59 patients available for follow-up, the risk of recurrent <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> remained at approximately 20% per year throughout the 9 year observation period </plain></SENT>
<SENT sid="4" pm="."><plain>The recurrence rate was the same regardless of age, sex, previous <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo>, or whether <z:hpo ids='HP_0011010'>chronic</z:hpo> AF or intermittent AF were present </plain></SENT>
<SENT sid="5" pm="."><plain>Only 7 (12%) died from a second <z:hpo ids='HP_0001297'>stroke</z:hpo>, however </plain></SENT>
<SENT sid="6" pm="."><plain>The high annual rate of recurrence and lack of controlled therapeutic trials in this population of patients warrant a prospective study to define the benefits and relative risks of <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy in AF due to NVHD </plain></SENT>
</text></document>